New alpha-emitting radiopharmaceutical therapy achieves strong responses in advanced prostate cancer
A new alpha-emitting radiopharmaceutical therapy (RPT) for advanced prostate cancer was well tolerated, with no dose-limiting toxicities observed, and showed encouraging signs of antitumor activity, according to a phase 1…